SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD

Review checklist: Ida B. Wells (HR-ET022)
All records · Back to the record · Dossier (sources.md) · Terminology · Report a problem · Comments
Everything a reviewer needs to judge, gathered from the record. Release status: draft.
- 15judgment calls in the dossier
- 0protocol deviations
- 4orders and referrals without results in the record
- 1evidence items to check (retrospective or sensitive claims, unconfirmed diagnoses)
Review status
| Review | Status | Reviewer | Date | Notes |
|---|
| schema validation | not_started | | | Run scripts/build.ps1 -Conformance. |
| clinical review | not_started | | | Awaiting clinician review; check the race-free eGFR values (creatinine 40, creatinine with cystatin C 38) and the race-based value for comparison, the G3b A2 staging, the kidney failure risk estimate, the sequencing of losartan and dapagliflozin with potassium and creatinine checks, the statin for an adult over 50 with eGFR below 60, vitamin D replacement, and the APOL1 counseling. |
| provenance review | not_started | | | Sources: the National Park Service, the National Women's History Museum, Women in World History (Encyclopedia.com), the Tennessee Encyclopedia and the University of Chicago Library finding aid. The Library of Congress, the Chicago Defender, Paula Giddings's biography and Crusade for Justice could not be read directly. |
| safe messaging review | not_started | | | No mental health claim is made; mood screening is synthetic and below the threshold for a safety assessment. Her death is stated once, without speculation about its cause beyond kidney disease or uremia as the sources give it. |
Judgment calls (dossier editorial resolutions)
- Recent-death rule. She died in 1931, so the rule does not apply. The record still uses only what the cited sources say about her health, which is very little: the brief final illness and its cause, kidney disease or uremia (CLM-0008).
- What is documented and what is interpretation. Her death after a brief illness from kidney disease (uremia) is D. Whether she had chronic kidney disease before that illness, and its cause, is not recorded; CLM-0009 states this as R with certainty “possible” and names the possibilities without choosing one. The modern episode is linked to these claims as a teaching anchor, not as a diagnosis of her real kidneys. No other illness, symptom or treatment from her life was found in the fetched sources, and none is added.
- What could not be verified and was left out. The Chicago Defender’s report of her death, Paula Giddings’s biography Ida: A Sword Among Lions and Crusade for Justice itself could not be read directly, so nothing is taken from them beyond what the fetched sources report (the title and editor of the autobiography). The Library of Congress pages could not be fetched (blocked). No fetched source names the day the final illness began, its symptoms or its course, so none is given. The age, name and cause of death of the infant brother beyond what Women in World History says are not used; a sister’s disability mentioned in one source is not used, because it is not needed and would add a health fact about another real person.
- Conflicts. Death date: March 25, 1931 (National Park Service, Tennessee Encyclopedia, Women in World History) is preferred; March 15 (National Women’s History Museum) and March 21 (University of Chicago Library) are recorded as conflicting alternatives. Age at death: 68 by her birth date; the Tennessee Encyclopedia says sixty-nine. The year she began the autobiography is given as 1927 by the University of Chicago Library and is used only in the timeline. The NAACP claim keeps both the founder status and her exclusion from the founding list.
- Display name and alias. The display name is “Ida B. Wells.” She used “Ida B. Wells-Barnett” after her marriage; it appears in no other record and is the only alias. No other figure who has a record is named.
- Index age and dates. The index visit on January 5, 2026 maps to January 5, 1931, when she was 68, about ten weeks before her death. The synthetic date of birth is July 16, 1957 (shift 95 years). The chronic-care visits on January 20, February 3 and March 3, 2026 and the annual wellness visit on February 17, 2026 map to the same days of 1931, all before the earliest reported death date (March 15) and before any reported final illness. The short window is the reason for the compressed schedule: two weeks to the consultation, two weeks after losartan, and four weeks after dapagliflozin, which are the CMID intervals for these checks. Checks planned after the last visit (potassium and creatinine after the losartan increase, urine albumin, hemoglobin, PTH and vitamin D at three months, and the nephrology review) are recorded as ordered or due; no result is invented for them. There is no past medical history before the index date, because none is documented.
- No sick visit. An acute illness weeks before her documented brief final illness would read as a hypothesis about that illness, so no sick visit is added. Sick-day rules for losartan and dapagliflozin are taught at every visit instead.
- Synthetic clinical picture. Every finding is synthetic. Following the presenting-problem pattern, intake records tiredness and ankle swelling with abnormal kidney tests (R94.4) and an elevated blood pressure reading (R03.0), both resolved at two weeks when the repeat urine test, the outside result, the ultrasound and home readings established hypertensive chronic kidney disease G3b A2 (I12.9, N18.32), anemia of chronic kidney disease (D63.1) and vitamin D deficiency (E55.9), all recorded then. Intake text shows only what was known at intake. Laboratory values are chosen so that the race-free CKD-EPI 2021 equations give eGFR 40 (creatinine) and 38 (creatinine with cystatin C); the script also computes the older race-based value (44) and the outside result two years earlier (64 race-based, 59 race-free) for the equity teaching point. The kidney failure risk (6.6% at 5 years, 2.2% at 2 years) is computed with the four-variable equation. Qualitative results (urinalysis, protein electrophoresis and free light chains, hepatitis and HIV serology, ultrasound, ECG, fundi) appear only in note text. Height (157 cm) and weights are synthetic.
- Equity in diagnosis. The teaching point is that a race coefficient once raised eGFR for Black patients, so her outside result two years earlier was reported as normal; the race-free equation shows the disease then. The record presents this as a feature of the equation and the system, citing the NKF-ASN Task Force, and does not attribute it to any person. The consultant also names APOL1-associated disease as possible without making ancestry a diagnosis.
- APOL1 testing. Offered with counseling at the consultation; she chose to defer it (GOAL-004, INT-008). No genetic result exists in the record, so no genetic claim is made about a real person.
- Real people. Her husband appears in the marriage claim and as part of her household only; her daughter appears only as the editor of the autobiography; her parents and infant brother appear only in the family history. No modern decision, statement or health fact is attributed to any real person.
- Medicines. Naproxen (over the counter) is stopped at intake and named only in text. Losartan 50 mg, then 100 mg; dapagliflozin 10 mg, started two weeks after losartan so that each eGFR change can be read; atorvastatin 20 mg without a routine repeat lipid panel, as KDIGO and the CMID advise (the ACC/AHA approach of repeat testing differs); vitamin D3; acetaminophen. Finerenone is discussed and not used, because she does not have diabetes.
- Annual wellness visit. A subsequent annual wellness visit at 68 (HCPCS G0439 and CPT 99497 in plain text) with the Mini-Cog, PHQ-2, AUDIT-C and Timed Up and Go; mammogram, bone density scan and a stool immunochemical test ordered; hepatitis B dose 2, RSV and recombinant zoster dose 1 given; and advance care planning that records her own synthetic wishes about kidney replacement options (transplant assessment, home dialysis preferred to center dialysis, conservative care explained) with an unnamed agent.
- Focused visits. The three chronic-care follow-ups (two weeks with the consultation, two weeks after losartan, and four weeks after dapagliflozin) are documented as focused visits on the CMID chronic kidney disease, hypertension and anemia monographs, KDIGO 2024, the KDIGO 2021 blood pressure guideline, the KDIGO 2017 CKD-MBD update and the 2025 AHA/ACC guideline. No protocol deviation occurred within the episode: each potassium and creatinine check fell within the two-to-four-week window; items due after the last visit are recorded as due or ordered.
- Consultation. The referral and the consultation by Emeka Lindqvist-Moore, MD (a fictional nephrologist), on the day of the two-week visit, are S. The consultant answers the six referral questions in line with what the record shows afterwards: hypertensive kidney disease most likely, APOL1-associated disease possible, no biopsy now; race-free staging confirmed, with cystatin C for decisions that depend on accuracy; APOL1 testing offered and deferred by her; losartan, then dapagliflozin, then losartan 100 mg (all done, with potassium at most 4.9 mmol/L and an eGFR dip of about 10%); vitamin D replacement with PTH rechecked at three months (due); and nephrology review at three months, with transplant evaluation when eGFR approaches 20.
Protocol deviations
Checks the monitoring protocol called for that the schedule did not perform. Each is recorded with its outcome and corrective action, never filled with an invented result.
None.
Orders and referrals without results in the record
| Visit | Type | Item | Status | Detail |
|---|
2026-01-20 Progress note 02 (C-CDA) | Laboratory | Potassium, sodium, bicarbonate, urea nitrogen, creatinine and eGFR | Ordered | Losartan started today; check in two weeks |
2026-02-17 Progress note 04 (C-CDA) | Prevention | Breast cancer screening | Ordered | Mammogram every two years to 74; last one more than two years ago |
2026-02-17 Progress note 04 (C-CDA) | Prevention | Colorectal cancer screening | Ordered | Stool immunochemical test, her choice, to avoid bowel preparation fluids and sedation while her kidney medicines are new |
2026-02-17 Progress note 04 (C-CDA) | Prevention | Bone density (DXA) | Ordered | Women 65 and older; none on record; kidney disease adds to fracture risk |
Evidence to check
Retrospective claims (R)
| Claim | Statement | Certainty |
|---|
| CLM-0009 | Whether she had chronic kidney disease before her final illness, and what caused her kidney failure, is not recorded in any source consulted; a short final illness ending in uremia is compatible with acute kidney failure, with chronic kidney disease made worse by an acute illness, or with long-standing kidney disease that had not been recognized. | possible |
Sensitive claims
None.
Diagnoses not confirmed
None.
Notes to read
Every note in the record, with its type. All clinical content is synthetic.
Abnormal results
| Date | Result | Value | Flag |
|---|
| 2026-01-05 | Urea nitrogen | 28 mg/dL (high) | High |
| 2026-01-05 | Creatinine | 1.42 mg/dL (high) | High |
| 2026-01-05 | eGFR, creatinine (CKD-EPI 2021, race-free) | 40 mL/min/1.73 m² (low) | Low |
| 2026-01-05 | Cystatin C | 1.68 mg/L (high) | High |
| 2026-01-05 | eGFR, creatinine and cystatin C (CKD-EPI 2021, race-free) | 38 mL/min/1.73 m² (low) | Low |
| 2026-01-05 | Urine albumin-to-creatinine ratio | 240 mg/g (high) | High |
| 2026-01-05 | Hemoglobin | 11.2 g/dL (low) | Low |
| 2026-01-05 | Parathyroid hormone, intact | 84 pg/mL (high) | High |
| 2026-01-05 | 25-hydroxyvitamin D | 17 ng/mL (low) | Low |
| 2026-01-05 | Total cholesterol | 214 mg/dL (high) | High |
| 2026-01-05 | LDL cholesterol | 136 mg/dL (high) | High |
| 2026-01-20 | Urine albumin-to-creatinine ratio | 228 mg/g (high) | High |
| 2026-02-03 | Urea nitrogen | 30 mg/dL (high) | High |
| 2026-02-03 | Creatinine | 1.5 mg/dL (high) | High |
| 2026-02-03 | eGFR, creatinine (CKD-EPI 2021, race-free) | 38 mL/min/1.73 m² (low) | Low |
| 2026-03-03 | Urea nitrogen | 31 mg/dL (high) | High |
| 2026-03-03 | Creatinine | 1.56 mg/dL (high) | High |
| 2026-03-03 | eGFR, creatinine (CKD-EPI 2021, race-free) | 36 mL/min/1.73 m² (low) | Low |